Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
How Should the World Pay for a COVID-19 Vaccine?
1 July 2020
This year’s OHE lecture addresses the question: how should the world pay for a COVID-19 vaccine? Adrian Towse, Emeritus Director of OHE and Senior Research Fellow…
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
1 June 2020
In the 2017 Industrial Strategy, the Government committed to increasing investment in UK Research and Development to the OECD-average of 2.4% of Gross Domestic Product (GDP)…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
1 January 2020
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting…
Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries
29 October 2019
New research by the Office of Health Economics (OHE) concludes the proposed International Price Index effectively outsources pharmaceutical policy decisions to countries that “give the government…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
OHE, in collaboration with RAND Europe, University College London (UCL) and University of Manchester (UoM), has been awarded a new research grant from Cancer Research UK in partnership with Greater Manchester Health & Social Care Partnership (GMHSCP) to further explore the potential of implementing outcome-based payments for cancer treatments.
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
The Trump Administration proposed an International Pricing Index for reimbursing physician-administered Medicare drugs. A conservative thought leader proposed a different basket of ‘market-oriented’ countries. These differ…
Data Governance Arrangements for Real-world Evidence in Japan
12 September 2019
A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…